Methamphetamine
Desoxyn, Methamphetamine (methamphetamine) is a small molecule pharmaceutical. Methamphetamine was first approved as Desoxyn on 1982-01-01. It is used to treat attention deficit disorder with hyperactivity, narcolepsy, and obesity in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Desoxyn (generic drugs available since 2010-04-21, discontinued: Methampex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methamphetamine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DESOXYN | AJENAT PHARMS | N-005378 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
334 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 14 | 16 | 3 | 3 | 16 | 48 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 8 | — | 2 | 5 | 15 |
| Depression | D003863 | — | F33.9 | 1 | — | 1 | 3 | 4 | 9 |
| Dual (psychiatry) diagnosis | D017831 | — | — | — | — | — | 2 | 1 | 3 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 1 | 1 | 2 |
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | 1 | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | 1 | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | 1 | — | 2 |
| Nonvital tooth | D019553 | — | — | — | — | — | 1 | 1 | 2 |
| Neurodevelopmental disorders | D065886 | — | F89 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | 1 | — | 2 | 4 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 1 | — | — | 1 |
| Critical illness | D016638 | — | — | — | — | 1 | — | — | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | 1 | — | — | 1 |
| Pain management | D059408 | — | — | — | — | 1 | — | — | 1 |
| Periodontal diseases | D010510 | — | K05.6 | — | 1 | 1 | — | — | 1 |
| Dentin sensitivity | D003807 | — | — | — | 1 | 1 | — | — | 1 |
| Ocular motility disorders | D015835 | EFO_1001990 | H50.54 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 9 | 12 | — | — | 9 | 29 |
| Hiv | D006678 | — | O98.7 | 2 | 3 | — | — | 7 | 10 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 1 | — | — | 3 | 5 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | 1 | 2 | — | — | 1 | 4 |
| Hiv seropositivity | D006679 | — | — | — | 1 | — | — | 1 | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | 1 | — | — | 1 | 2 |
| Colorectal neoplasms | D015179 | — | — | 1 | 1 | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | 1 | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | 1 | 1 | — | — | — | 1 |
| Neurobehavioral manifestations | D019954 | EFO_0004364 | — | 1 | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dental caries | D003731 | EFO_0003819 | K02 | 1 | — | — | — | 10 | 11 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | 3 | 6 |
| Dental restoration failure | D019232 | — | — | 1 | — | — | — | 1 | 2 |
| Affect | D000339 | — | — | 1 | — | — | — | 1 | 2 |
| Cognition | D003071 | EFO_0003925 | — | 1 | — | — | — | — | 1 |
| Cardiovascular abnormalities | D018376 | EFO_0003848 | — | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Alcohol-related disorders | D019973 | — | F10 | 1 | — | — | — | — | 1 |
| Sexual abstinence | D012746 | — | — | 1 | — | — | — | — | 1 |
| Chemically-induced disorders | D064419 | — | — | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 4 | 4 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 3 | 3 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | — | 3 | 3 |
| Cocaine-related disorders | D019970 | — | F14 | — | — | — | — | 3 | 3 |
| Amblyopia | D000550 | HP_0000646 | H53.00 | — | — | — | — | 3 | 3 |
| Bone resorption | D001862 | — | — | — | — | — | — | 3 | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 3 | 3 |
| Myopia | D009216 | EFO_0003927 | H52.1 | — | — | — | — | 3 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 2 | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | — | 2 | 2 |
Show 63 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methamphetamine |
| INN | metamfetamine |
| Description | Methamphetamine[note 1] (contracted from N-methylamphetamine) is a potent central nervous system (CNS) stimulant that is mainly used as a recreational drug and less commonly as a second-line treatment for attention deficit hyperactivity disorder and obesity. Methamphetamine was discovered in 1893 and exists as two enantiomers: levo-methamphetamine and dextro-methamphetamine.[note 2] Methamphetamine properly refers to a specific chemical substance, the racemic free base, which is an equal mixture of levomethamphetamine and dextromethamphetamine in their pure amine forms, but the hydrochloride salt, commonly called crystal meth, is widely used. Methamphetamine is rarely prescribed over concerns involving human neurotoxicity and potential for recreational use as an aphrodisiac and euphoriant, among other concerns, as well as the availability of safer substitute drugs with comparable treatment efficacy such as Adderall and Vyvanse. Dextromethamphetamine is a stronger CNS stimulant than levomethamphetamine.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@@H](C)Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 537-46-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201201 |
| ChEBI ID | 6809 |
| PubChem CID | 1206 |
| DrugBank | DB01577 |
| UNII ID | 44RAL3456C (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Methamphetamine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 39,794 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,842 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use